OVID

2.2055.77%
MA

Margaret Alexander

CEO, President & Director

Ms. Margaret Alexander, also known as Meg, is CEO of Ovid Therapeutics Inc. from January 1, 2026 and serves as its President since September 2024 and served as Chief Strategy Officer since June 2023 until October 2024 and served as Chief Corporate Affairs Officer from August 2022 until 2023. She served as COO of Ovid Therapeutics Inc. until January 1, 2026. Ms. Alexander has worked in the biopharmaceutical industry and has played a key role in launching more than 25 new medicines – many for intractable and devastating conditions such as ALS, HIV, multiple sclerosis, rare epilepsies, Batten’s disease, cardiovascular disease and cancer. She has advised and led campaigns for large healthcare organizations, including: Pfizer, Novartis, Amgen, Janssen, Boehringer Ingelheim, Eli Lilly, BioMarin, Nestle and many others. In her role as Corporate Affairs Office at Ovid, she oversees stakeholder relations including: patient community engagement, government affairs, communications and Investor Relations. Prior to Ovid, she founded and led the Reputation & Risk Management Group, a division in Syneos Health, one of the world’s largest clinical research organizations, in which she grew the practice from one to 25 employees. Ms. Alexander was named a “Disruptor” and a “Rising Star” in her industry by PM360 and the Healthcare Business Women’s Association. She helped organize and marshal the biotech industry’s response to the war in Ukraine by coordinating contributions of monetary and drug resources to non-governmental organizations who were validated by the Ukrainian Ministry of Health. Ms. Alexander began her career at Ruder Finn and holds a Bachelor of Business Administration from the College of William & Mary.

Positions